Free Trial
→ $5,000 DOGE check? (From Altimetry) (Ad)

Surrozen Q4 2022 Earnings Report

Surrozen logo
$11.20 -0.35 (-3.03%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Surrozen EPS Results

Actual EPS
-$0.45
Consensus EPS
-$6.75
Beat/Miss
Beat by +$6.30
One Year Ago EPS
N/A

Surrozen Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Surrozen Announcement Details

Quarter
Q4 2022
Date
3/22/2023
Time
N/A

Conference Call Resources

Surrozen Earnings Headlines

Surrozen (NASDAQ:SRZN) Stock Quotes, Forecast and News Summary
January 30, 2025 | benzinga.com
HC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy Recommendation
January 30, 2025 | msn.com
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
February 22, 2025 | Altimetry (Ad)
H.C. Wainwright sets $32 target on Surrozen stock with Buy rating
January 30, 2025 | msn.com
Surrozen initiated with a Buy at H.C. Wainwright
January 30, 2025 | markets.businessinsider.com
Here's Why We're A Bit Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Situation
January 22, 2025 | uk.finance.yahoo.com
See More Surrozen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email.

About Surrozen

Surrozen (NASDAQ:SRZN), a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

View Surrozen Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles